Submission 136
Medicines Australia
Submitter group: Industry bodies.
An AI model identified the submitter group and wrote the summary, key points and recommendation summaries. Counts do not measure importance or merit.
Summary
Read the original submission for the full text.
Medicines Australia describes AI's potential for health research and medicines development, while noting pricing and health technology assessment pressures may limit benefits. It recommends investment, collaboration and commercialisation policies, internationally aligned regulation, and nationally consistent health data access and governance, with privacy safeguards and public trust central.
Key points
Quotes are the submitter’s own words. Text taken from documents, including scanned pages read by text-recognition software, can differ from the PDF. Check the original. Listed in the same order as on the submission’s page in the interactive guide.
Says that for the pharmaceutical industry AI is already transforming how medicines are discovered, developed, tested and monitored.
For the innovative pharmaceutical industry, AI is already transforming the way medicines are discovered, developed, tested and monitored.
Argues that Australia's attractiveness for clinical research investment will increasingly depend on supporting AI-enabled approaches through data access, regulation and infrastructure.
As AI-enabled clinical development becomes standard practice globally, Australia’s competitiveness as a destination for clinical research investment will increasingly depend on its ability to support these approaches through appropriate data access, regulatory settings and research infrastructure. Failure to keep pace with competing jurisdictions may reduce Australia’s attractiveness for future research and development investment.
Argues that divergence from regulators such as the FDA and EMA could add compliance complexity and reduce Australia's attractiveness for AI-enabled clinical research.
Divergence from emerging approaches adopted by leading regulators such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) could increase compliance complexity, create duplication of effort, and reduce Australia's attractiveness as a location for AI-enabled clinical research.
Says Australia's health data landscape is fragmented, which can limit access to datasets needed for research and AI development.
Fragmentation can increase administrative burden and limit access to datasets needed for research and AI development. These barriers may constrain Australia's ability to fully realise the value of its health and medical data assets for research, innovation and medicines development.
Says public trust, privacy protections and transparency must remain central to any approach to health data use.
At the same time, maintaining public trust must remain central to any approach to health data use. AI systems rely on access to large and diverse datasets, making strong privacy protections, transparency and appropriate consent frameworks essential.
Recommendations
Recommendations are shown beside the submission’s own words. Listed in the same order as on its page in the interactive guide.
Support attraction and retention of highly skilled AI, data science and biomedical talent.
Australia requires policy settings that encourage sustained investment in research and development, strengthen pathways for translating research into commercial outcomes, and support the attraction and retention of highly skilled AI, data science and biomedical talent.
Support AI adoption in health and medical research through policies encouraging investment, collaboration and commercialisation.
Support adoption of AI in health and medical research through policies that encourage industry investment, research collaboration and translation of research into commercialisation outcomes.
Consider AI-assisted evidence generation in medicines development, including clinical trial design, real-world evidence generation and pharmacovigilance.
Consideration will be needed regarding the use of AI-assisted evidence generation in medicines development, including applications in clinical trial design, real-world evidence generation and pharmacovigilance.
Maintain fit-for-purpose, internationally aligned regulatory frameworks for AI-enabled medicine development.
Maintain fit-for purpose, internationally aligned regulatory frameworks for AI-enabled medicine development.
A program corrected obvious text-recognition errors in this quote for display.
Enable secure, ethical health-data access while protecting patient privacy, with transparency about collection, linking, analysis and governance.
The challenge for policymakers is therefore not whether health data should be used to support research and innovation, but how frameworks can enable secure and ethical access while protecting patient privacy and ensuring transparency regarding how data are collected, linked, analysed and governed.
Consider standardised data access requirements, interoperability standards, streamlined approvals and clear governance to improve researcher and industry access while maintaining robust privacy safeguards.
Standardised data access requirements, interoperability standards, streamlined approval processes and clear governance arrangements could improve access to high-quality datasets for researchers and industry while maintaining robust privacy safeguards.
Establish a nationally consistent approach to health data access and governance to support responsible AI development, health research and medicines innovation.
Establish a nationally consistent approach to health data access and governance to support responsible AI development, health research and medicines innovation.
Read the original
In some quotes a program corrected obvious text-recognition errors for display.